Loading...
 
Back to the list
Mediterr J Rheumatol 2019;30(Supp 1):54-8
Article Links
From Basic Immunology to Clinical Practice: Bio-Originators versus Bio-Similars
Stamatis-Nick C. Liossis1,2, Georgia M. Konstantopoulou1
Authors Information

1Division of Rheumatology, Department of Internal Medicine, Patras University Hospital, Rion, Patras, Greece
2University of Patras Medical School, Rion, Patras, Greece

Keywords: Bio-Originators, biosimilars, immunogenicity, pharmacovigilance
References
  1. Scheinberg MA, Kay J. The advent of biosimilar therapies in rheumatology—“O brave new world”. Nat Rev Rheumatol 2012;8:430-6. [https://doi.org/10.1038/nrrheum.2012.84] [PMID: 22664834]
  2. Kay J, Smolen JS. Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis 2013;72:1589-93. [https://doi.org/10.1136/annrheumdis-2012-203198] [PMID: 23897773]
  3. Dorner T, Strand V, Castaneda-Hernandez G, Ferraccioli G, Isaacs JD, Kvien TK, et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 2013;72:322-8. [https://doi.org/10.1136/annrheumdis-2012-202715] [PMID: 23253920]
  4. Morrow T, Felcone LH. Defining the difference: What makes biologics unique. Biotechnol Health 2004;1:24-9. [PMID: 23393437] [PMCID: PMC3564302]
  5. Kuhlmann M, Covic A The protein science of biosimilars. Nephrol Dial Transplant 2006;21(Suppl 5):v4-8. [https://doi.org/10.1093/ndt/gfl474] [PMID: 16959791]
  6. Azevedo V, Hassett B, Fonseca JE, Atsumi T, Coindreau J, Jacobs I, et al. Differentiating biosimilarity and comparability in biotherapeutics. Clin Rheumatol 2016;35(12):2877-86. [https://doi.org/10.1007/s10067-016-3427-2] [PMID: 27734233]
  7. US Food and Drug Administration. Information for consumers (biosimilars). http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm241718.htm; 2014. [Accessed on May 20, 2016].
  8. Pasina L, Casadei G, Nobili A. Biological agents and biosimilars: Essential information for the internist. Eur J Intern Med 2016;33:28-35. [https://doi.org/10.1016/j.ejim.2016.06.005] [PMID: 27342030]
  9. Declerck P, Farouk-Rezk M, Rudd P. Biosimilarity Versus Manufacturing Change: Two Distinct Concepts. Pharm Res 2016;33(2):261-8. [https://doi.org/10.1007/s11095-015-1790-3] [PMID: 26381277]
  10. McCamish M, Woollett G. Worldwide experience with biosimilar development. MAbs 2011;209-17. [https://doi.org/10.4161/mabs.3.2.15005] [PMID: 21441787] [PMCID: PMC3092622]
  11. Kvamme MK, Lie E, Uhlig T, Moger TA, Kvien TK, Kristiansen IS. Cost-effectiveness of TNF inhibitors versus synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies. Rheumatology (Oxford) 2015;54(7):1226-35. [https://doi.org/10.1093/rheumatology/keu460] [PMID: 25573840]
  12. Schneider CK, Vleminckx C, Gravanis I, Ehmann F, Trouvin JH, Weise M, et al. Setting the stage for biosimilar monoclonal antibodies. Nat Biotechnol 2012;30:1179-85. [https://doi.org/10.1038/nbt.2447] [PMID: 23222783]
  13. Hulse J, Cox C. In vitro functional testing methods for monoclonal antibody biosimilars. Bioprocess Int 2013;11:24-7.
  14. Kuhlmann M, Covic A. The protein science of biosimilars. Nephrol Dial Transplant 2006; 21(Suppl 5):v4-8. [https://doi.org/10.1093/ndt/gfl474] [PMID: 16959791]
  15. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol 2008; 19:411-9. [https://doi.org/10.1093/annonc/mdm345] [PMID: 17872902]
  16. Dranitsaris G, Dorward K, Hatzimichael E, Amir E. Clinical trial design in biosimilar drug development. Invest New Drugs 2013;31:479-87. [https://doi.org/10.1007/s10637-012-9899-2] [PMID: 23161336]
  17. Bendtzen K. Immunogenicity of anti-TNF-α biotherapies: I. Individualized medicine based on immunopharmacological evidence. Front Immunol 2015;6:152. [https://doi.org/10.3389/fimmu.2015.00152] [PMID: 25904915] [PMCID: PMC4389569]
  18. Scott C. A Decade of Characterization. Bioprocess Int 2012;10:58-61.
  19. Tsuruta LR, Lopes Dos Santos M, Moro AM. Biosimilars advancements: moving on to the future. Biotechnol Prog 2015;31:1139-49. [https://doi.org/10.1002/btpr.2066] [PMID: 25708573]
  20. Conlon HD, Thompson M, Ng CK, Rouse JC, Porter TJ. Analytical challenges during the development of a biosimilar. Presented at: Annual Meeting of the IBC Bioprocess International Conference; October 20-23, 2014; Boston, MA.
  21. European Medicines Agency. Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use, (http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128688.pdf; Accessed 15.05.15).
  22. European Medicines Agency (2013) Guideline on similar biological medicinal products.(http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/WC500142978.pdf; Accessed 23.04.14).
  23. US Food and Drug Administration (2012) Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf; Accessed 23.04.14).
  24. Chow SC, Endrenyi L, Lachenbruch PA, Yang L-Y, Chi E. Scientific factors for assessing biosimilarity and drug interchangeability of follow-on biologics. Biosimilars 2011;1:13-26. [https://doi.org/10.2147/BS.S20577]
  25. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002;1:457-62. [https://doi.org/10.1038/nrd818] [PMID: 12119747]
  26. Schellekens H. Biosimilar therapeutic agents: issues with bioequivalence and immunogenicity. Eur J Clin Invest 2004;34:797-9. [https://doi.org/10.1111/j.1365-2362.2004.01428.x] [PMID: 15606720]
  27. Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant 2006;21 Suppl 5:v9-12. [https://doi.org/10.1093/ndt/gfl476] [PMID: 16959792]
  28. Schellekens H, Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol 2004;251 Suppl 2:II4-9. [https://doi.org/10.1007/s00415-004-1202-9] [PMID: 15264106]
  29. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 2002;24:1720-40; discussion 1719. [PMID: 12501870]
  30. Van Schouwenburg PA, Van De Stadt LA, De Jong RN, Van Buren EE, Kruithof S, De Groot E, et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis 2013;72(1):104-9. [https://doi.org/10.1136/annrheumdis-2012-201445] [PMID: 22759910]
  31. Fasanmade AA, Adedokun OJ, Ford J, Hernandez D, Johanns J, Hu C, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 2009;65:1211-28. [https://doi.org/10.1007/s00228-009-0718-4] [PMID: 19756557] [PMCID: PMC2778780]
  32. Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007;46,64-60. [https://doi.org/10.2165/00003088-200746080-00002] [PMID: 17655372]
  33. Reinisch W, Smolen J. Biosimilar safety factors in clinical practice. Semin Arthritis Rheum 2015;44(6)S9-15. [https://doi.org/10.1016/j.semarthrit.2015.04.005] [PMID: 26058551]
  34. Lie G, Sciascia S, Cuadrado M. Biosimilar vs biological agents in rheumatology: When are biosimilar agents similar enough? Int Immunopharmacol 2015;27(2):220-3. [https://doi.org/10.1016/j.intimp.2015.04.022] [PMID: 25907240]
  35. Mendes De Abreu M, Strand V, Levy R, Araujo DV. Putting the value into biosimilar decision making. The judgment value criteria. Autoimmun Rev 2014;13(6):678-84. [https://doi.org/10.1016/j.autrev.2014.01.051] [PMID: 24440285]
  36. Garattini L, Curto A, Van De Vooren K. Western European markets for biosimilar and generic drugs: worth differentiating. Eur J Health Econ 2015;16:683-7. [https://doi.org/10.1007/s10198-015-0684-y] [PMID: 25791078]
  37. Weise M. Bielsky MC, De Smet K, Ehmann F, Ekman N, Narayanan G, et al. Biosimilars—why terminology matters. Nat Biotechnol 2011; 29:690-3. [https://doi.org/10.1038/nbt.1936] [PMID: 21822237]
  38. Beck A, Debaene F, Diemer H, Wagner-Rousset E, Colas O, Van Dorsselaer A, et al. Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies. J Mass Spectrom 2015;50:285-97. [https://doi.org/10.1002/jms.3554] [PMID: 25800010]